68 results
To investigate cerebral activation patterns after administration of an AChE-I (rivastigmine), compared to activation after placebo, in PD patients with VH.Secondly, to investigate whether cerebral activation changes after rivastigmine correlates…
Primary aim of the study is to evaluate the efficacy and safety of intramuscular magnesiumsulphate in CRPS I patients during 3 weeks dose escalation study.
The aim of this study is to prove the efficacy of 3 times daily 1 mg glycopyrronium bromide versus placebo in patients with PD with hypersalivation. Furthermore, the safety of glycopyrronium bromide used in the mentioned dosage will be further…
To investigate whether impairments of shifting between response sets underlie motor freezing in PD and to investigate the efficacy and the neural mechanism by which MPH improves gait and cognition in PD patients with FOG.
To evaluate the effect of treatment with BoNT on psychogenic jerks.
Primary aim of the study is to compare the efficacy and safety of two flowrates of ITB while maintaining a constant daily dose.
First aim of the study is to investigate whether a physical activity promotion program will result in a improvement in physical activity in sedentary patients with PD. Furthermore, the related health benefits will be analysed.
The objective of this project is to study the role of dopaminergic mechanisms in apathy, mood and HDD in patients with PD. What is the involvement of the dopaminergic neurotransmitter system in motivation and reward processes in PD and the clinical…
We hypothesize that bilateral globus pallidus internus (GPi) DBS produces greater functional improvement in PD than bilateral STN DBS because of a lower rate of complications.
To assess whether treatment with DBS can reduce or resolve TDD and if DBS can induce beneficial or side effects in particular psychiatric and or cognitive symptoms.
Our objective is to assess the effect of TRP depletion on mood and behavior in PD patients treated with STN DBS. By doing, this, we hope to be able to identify risk factors for and mechanisms underlying psychiatric side effects of STN DBS.…
1) to identify the effect of manipulating the electrical synapses in the IO on motor learning in healthy individuals during cerebellar specific motor adaptation tasks. 2) to identify the effect of manipulating the subthreshold oscillations in the IO…
The objective of the study is to determine whether exposure to the SpectraMax light therapy device, emitting light in a combined spectra of blue/green light (460 * 570 nm) with an intensity of approximately 1300 Lux, will be more effective in…
Determine the efficacy of atDCS as compared to ctDCS and sham stimulation in the improvement of executive functioning in PD-MCI.
Deulevodopa in combination with carbidopa is a combination in development for the treatment of patients with Parkinson*s disease.The effects of deulevodopa taken with carbidopa have not yet been tested in humans, and there are no available clinical…
The main purpose of the study is to investigate the safety and tolerability of MDV1634. Additional objectives of the study are to assess how quickly and to what extent MDV1634 is absorbed and eliminated from the body (pharmacokinetics), and the…
* Part A: To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of increasing doses of YTX-7739 in healthy subjects. * Part B: To study the effect of food on pharmacokinetics of YTX-7739 in a selection of subjects who…
The study objective is primarily to measure the effect of an online cognitive training in patients with mild cognitive complaints in PD. An online training, specifically altered for PD patients (BrainGymmer) will be compared with an active online…
To investigate whether treatment of dystonia causing varus tilt of the hindfoot in Parkinson*s disease is more effective when botulinum toxin type A is combined with complementary functional gait training compared to botulinum toxin type A treatment…
Primary ObjectiveThe primary objective of the study is to determine the effect of ND0612 on daily *ON* time without troublesome dyskinesia (defined as the sum of "ON" time without dyskinesia and *ON* time with non-troublesome dyskinesia)…